Filing Flows › Medifast (MED) › Q3 2026
Medifast (MED) Q3 2026 earnings results (third quarter 2026)
10-Q filed Oct 26, 2026
Medifast (MED) reported revenue of $72.0M for the third quarter 2026 (Q3 2026), -19% from a year earlier and -6% from the quarter before. Operating margin was -26.9%, net loss $17.5M (24.3% of revenue).
Medifast, Q3 2026: revenue $72.0M (-19% year over year), operating margin -26.9%, net loss $17.5M, operating cash flow $3.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $72.0M | -6% | -19% |
| Operating profit | −$19.4M | — | — |
| Net earnings | −$17.5M | — | — |
| Operating cash flow | $3.3M | +94% | -73% |
| Free cash flow | $2.9M | +294% | -73% |
What changed
Revenue was $72.0M in Q3 2026, down 19% year over year and down 6% from the previous quarter.
Gross margin was 69.5%, down 0.1 points from Q3 2025. Operating costs exceeded revenue by $19.4M, an operating margin of -26.9%. Operating expenses grew 5% against a revenue fall of 19%. The quarter ended with a net loss of $17.5M, wider than the previous quarter's $3.1M loss.
Operating cash flow was $3.3M (down 73% year over year). Non-cash charges added back $2.4M of depreciation and amortization and $1.9M of share-based compensation. Working capital and other items added $16.6M. Capital expenditures of $427K left free cash flow of $2.9M.
Questions
What was Medifast's revenue in the third quarter 2026?
Medifast (MED) reported revenue of $72.0M for the third quarter 2026 (Q3 2026), -19% from a year earlier and -6% from the quarter before.
Was Medifast profitable in the third quarter 2026?
Operating loss was $19.4M (-26.9% of revenue) and net loss $17.5M.
Source: Medifast 10-Q on SEC EDGAR.